Indegene Ltd
NSE: INDGN BSE: 544172
Incorporated in 1998, Indegene Ltd provides solutions consisting of analytics, technology and commercial, medical, regulatory and safety services to life science and health care organizations[1]
₹509
52W: ₹414 — ₹633
PE 57.8 · Book ₹86.4 · +489% vs bookMarket Cap₹12,254 Cr
Stock P/E57.8Price to Earnings
ROCE14.3%Return on Capital
ROE10.7%Return on Equity
Div. Yield0.4%Face Value ₹2
Strengths
- +Company is almost debt free.
- +Company has been maintaining a healthy dividend payout of 17.3%
- +Debtor days have improved from 119 to 84.8 days.
Weaknesses
- −Company has a low return on equity of 12.0% over last 3 years.
- −Working capital days have increased from 162 days to 261 days
Shareholding Pattern
Promoters0%
FIIs10.27%
DIIs8.29%
Public81.43%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| FIIs | 3.79% | 4.82%▲1.0 | 5.03%▲0.2 | 5.24%▲0.2 | 10.04%▲4.8 | 11.3%▲1.3 | 11.48%▲0.2 | 10.27%▼1.2 |
| DIIs | 3.84% | 3.17%▼0.7 | 3.99%▲0.8 | 4.96%▲1.0 | 7.2%▲2.2 | 6.95%▼0.3 | 8.06%▲1.1 | 8.29%▲0.2 |
| Public | 92.38% | 92.01%▼0.4 | 91.01%▼1.0 | 89.8%▼1.2 | 82.75%▼7.0 | 81.74%▼1.0 | 80.44%▼1.3 | 81.43%▲1.0 |
Financial Statements
| Metric | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 260 | 272 | 259 | 282 | 287 | 267 | 256 | 307 | 290 | 368 |
| Expenses | 223 | 226 | 219 | 235 | 235 | 227 | 219 | 236 | 252 | 265 |
| Operating Profit | 37 | 46 | 40 | 46 | 52 | 40 | 37 | 71 | 38 | 103 |
| OPM % | 14% | 17% | 15% | 16% | 18% | 15% | 14% | 23% | 13% | 28% |
| Net Profit | 30 | 49 | 33 | 45 | 50 | 54 | 45 | 60 | 35 | 72 |
| EPS ₹ | 1.33 | 2.2 | 1.36 | 1.87 | 2.08 | 2.26 | 1.88 | 2.49 | 1.45 | 2.99 |
AI Insights
Revenue Trend
Mar 2026 revenue at ₹1,221Cr, up 11.6% YoY. OPM at 20%.
Debt Position
Borrowings at ₹70Cr. Debt-to-equity ratio: 0.03x. Healthy balance sheet.
Capex Cycle
CWIP at ₹12Cr (11% of fixed assets). Moderate ongoing capital expenditure.
Institutional Flow
DIIs: 8.29% (+4.45pp change). FIIs: 10.27% (+6.48pp change). Promoters hold 0%.
Margin & Efficiency
ROCE improving from 0% (Mar 2019) to 14% (Mar 2026). Working capital days: 261.
Valuation
PE 57.8x with 14.3% ROCE. Price is 489% above book value of ₹86.4. Dividend yield: 0.4%.
Recent Announcements
- Announcement under Regulation 30 (LODR)-Earnings Call Transcript 6 May - Transcript of earnings conference call on financial results for the quarter and year ended March 31, 2026
- Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order 5 May - Income tax department raised ₹43.69 crore demand for AY 2023-24 over transfer pricing adjustments.
- Announcement under Regulation 30 (LODR)-Press Release / Media Release 4 May - Indegene named a Leader in ISG Provider Lens 2026 for life sciences digital services, third straight year.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 1 May
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 30 Apr - Audio recording of Indegene's Q4 and FY26 earnings call released on April 30, 2026.
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Transcript